Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Brukinsa® (zanubrutinib) – New orphan indication
September 1, 2021 - BeiGene announced the FDA approval of Brukinsa (zanubrutinib), for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
